- Home
- SLRX
as 11-22-2024 4:00pm EST
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 2.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 42.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.26 - $7.27 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Salarius Pharmaceuticals Inc. News
SLRX Breaking Stock News: Dive into SLRX Ticker-Specific Updates for Smart Investing
Associated Press Finance
9 days ago
Salarius: Q3 Earnings Snapshot
Associated Press Finance
3 months ago
Salarius: Q2 Earnings Snapshot
MT Newswires
4 months ago
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires
4 months ago
Sector Update: Health Care Stocks Advance in Afternoon Trading
MT Newswires
4 months ago
Top Midday Decliners
MT Newswires
4 months ago
Salarius Pharmaceuticals Says FDA Placed Cancer Treatment Trial on Partial Hold; Shares Fall
GlobeNewswire
5 months ago
Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting
GlobeNewswire
5 months ago
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Compare SLRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLRX Salarius Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.